Receptos Announces Completion of Initial Public Offering of Common Stock
May 14 2013 - 9:39PM
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company
developing therapeutic candidates for the treatment of immune and
metabolic diseases, today announced the completion of its initial
public offering of 5,200,000 shares of its common stock at an
initial public offering price of $14.00 per share. Receptos'
common stock is listed on the Nasdaq Global Market under the symbol
"RCPT." In addition, Receptos has granted the underwriters a
30-day option to purchase up to an additional 780,000 shares of
common stock to cover over-allotments, if any.
Credit Suisse Securities (USA) LLC, Leerink Swann LLC and BMO
Capital Markets acted as joint book-running managers for the
offering. Wedbush PacGrow Life Sciences acted as a co-manager.
A registration statement relating to these securities was
declared effective by the Securities and Exchange
Commission on May 8, 2013. The offering was made only by means
of a prospectus. Copies of the prospectus relating to the offering
may be obtained from Credit Suisse Securities (USA) LLC, Attention:
Prospectus Department, One Madison Avenue, New York, NY 10010,
Telephone: (800) 221-1037, Email:
newyork.prospectus@credit-suisse.com; from Leerink Swann LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, MA 02110, Telephone: (800) 808-7525, Email:
syndicate@leerink.com; or from BMO Capital Markets, Attention:
Equity Syndicate Department, 3 Times Square, New York, NY 10036,
Telephone: (800) 414-3627, Email: bmoprospectus@bmo.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or other jurisdiction in which such
an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or other jurisdiction.
About Receptos
Receptos is a biopharmaceutical company developing therapeutic
candidates for the treatment of immune and metabolic diseases. The
company's lead program, RPC1063, is a sphingosine 1-phosphate 1
receptor (S1P1R) small molecule modulator candidate for immune
indications, including relapsing multiple sclerosis (RMS) and
inflammatory bowel disease (IBD). The company is also developing
RPC4046, an anti-interleukin-13 (IL-13) antibody for an
allergic/immune-mediated orphan disease, eosinophilic esophagitis
(EoE). Receptos has established expertise in high resolution
protein crystal structure determination, biology and drug discovery
for G-protein-coupled receptors (GPCRs).
CONTACT: Media and Investor Contact:
Graham K. Cooper
Chief Financial Officer, Receptos
(858) 652-5708
gcooper@receptos.com
RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart
From Sep 2024 to Oct 2024
RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart
From Oct 2023 to Oct 2024